Jeremy Presland

Statistics

Publications

Citations

H-Index

Active since

1991

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

WuXi AppTec (China)

Organogenesis (United States)

Jeremy Presland is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and ligand binding.

ORCID

Publications per year

1991–2022

Publications

An orally available non-nucleotide STING agonist with antitumor activity

Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux et al. · Science · 2020 · 660 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer

Wonsuk Chang, Michael D. Altman, Charles A. Lesburg et al. · Journal of Medicinal Chemistry · 2022 · 137 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Discovery of 8-Amino-imidazo[1,5-<i>a</i>]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis

Jian Liu, Deodial Guiadeen, A. D. Krikorian et al. · ACS Medicinal Chemistry Letters · 2015 · 38 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications

Jongwon Lim, Michael D. Altman, James Α. Baker et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 32 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation

G. Smith, Michael D. Altman, Brian M. Andresen et al. · Bioorganic & Medicinal Chemistry Letters · 2017 · 25 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +6

1–5 of 14